Trial name | RE-COVER | RE-COVER II | EINSTEIN-DVT | EINSTEIN-PE | AMPLIFY | Hokusai-VTE |
---|---|---|---|---|---|---|
Year of Publication [Ref] | 2009 [15] | 2014 [16] | 2010 [17] | 2012 [18] | 2013 [19] | 2013 [20] |
Design | Double-blinded | Double-blinded | PROBE | PROBE | Double-blinded | Double-blinded |
Number of Patients | 2539 | 2589 | 3449 | 4832 | 5395 | 8292 |
Indication for Anticoagulation | Acute VTE | Acute VTE | Acute DVT | Acute PE | Acute VTE | Acute VTE |
DOAC Treatment Protocol | Dabigatran 150 mg twice daily | Dabigatran 150 mg twice daily | Rivaroxaban 15 mg twice daily for 3 weeks; then 20 mg once daily | Rivaroxaban 15 mg twice daily for 3 weeks; then 20 mg once daily | Apixaban 10 mg twice daily for days; then 5 mg twice daily | Edoxaban 60 once daily; patients with CrCl 30–50 mL/min, body weight ≤60 kg, or receiving strong P-glycoprotein inhibitors: edoxaban 30 mg once daily |
Non-inferiority Margin for Hazard Ratio | 2.75 | 2.75 | 2.0 | 2.0 | 1.8 | 1.5 |
Need for initial Parenteral Anticoagulation | Yes | Yes | No | No | No | Yes |
Duration of Therapy (months) | 6 | 6 | 3, 6, or 12 | 3, 6, or 12 | 6 | ≤12 |
TTR (%) | 60 | 57 | 58 | 63 | 61 | 64 |